Investigational Drug Information for Idraparinux
✉ Email this page to a colleague
What is the development status for investigational drug Idraparinux?
Idraparinux is an investigational drug.
There have been 5 clinical trials for Idraparinux.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2003.
The most common disease conditions in clinical trials are Venous Thrombosis, Thrombosis, and Pulmonary Embolism. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Summary for Idraparinux
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 866 |
| WIPO Patent Applications | 516 |
| Japanese Patent Applications | 245 |
| Clinical Trial Progress | Phase 3 (2003-09-01) |
| Vendors | 13 |
Recent Clinical Trials for Idraparinux
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation | Sanofi | Phase 3 |
| Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach | Sanofi | Phase 3 |
| Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs | Sanofi | Phase 3 |
Clinical Trial Summary for Idraparinux
Top disease conditions for Idraparinux
Top clinical trial sponsors for Idraparinux
US Patents for Idraparinux
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
